IL232664A0 - A small molecule enhancer for dendritic cell cancer vaccines - Google Patents

A small molecule enhancer for dendritic cell cancer vaccines

Info

Publication number
IL232664A0
IL232664A0 IL232664A IL23266414A IL232664A0 IL 232664 A0 IL232664 A0 IL 232664A0 IL 232664 A IL232664 A IL 232664A IL 23266414 A IL23266414 A IL 23266414A IL 232664 A0 IL232664 A0 IL 232664A0
Authority
IL
Israel
Prior art keywords
small molecule
dendritic cell
cell cancer
cancer vaccines
molecule enhancer
Prior art date
Application number
IL232664A
Other languages
English (en)
Hebrew (he)
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Publication of IL232664A0 publication Critical patent/IL232664A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
IL232664A 2011-11-22 2014-05-18 A small molecule enhancer for dendritic cell cancer vaccines IL232664A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161562497P 2011-11-22 2011-11-22
PCT/US2012/065236 WO2013078059A1 (en) 2011-11-22 2012-11-15 Small molecule enhancer for dendritic cell cancer vaccines

Publications (1)

Publication Number Publication Date
IL232664A0 true IL232664A0 (en) 2014-07-31

Family

ID=48470210

Family Applications (1)

Application Number Title Priority Date Filing Date
IL232664A IL232664A0 (en) 2011-11-22 2014-05-18 A small molecule enhancer for dendritic cell cancer vaccines

Country Status (9)

Country Link
US (3) US9284337B2 (cg-RX-API-DMAC7.html)
EP (2) EP2782994B1 (cg-RX-API-DMAC7.html)
JP (2) JP6240083B2 (cg-RX-API-DMAC7.html)
CN (2) CN106075450A (cg-RX-API-DMAC7.html)
AU (2) AU2012340887A1 (cg-RX-API-DMAC7.html)
CA (1) CA2856379A1 (cg-RX-API-DMAC7.html)
HK (1) HK1201871A1 (cg-RX-API-DMAC7.html)
IL (1) IL232664A0 (cg-RX-API-DMAC7.html)
WO (1) WO2013078059A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284337B2 (en) * 2011-11-22 2016-03-15 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
WO2016085943A1 (en) 2014-11-25 2016-06-02 Rastelli, Luca Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11000521B2 (en) 2015-08-03 2021-05-11 Institut Pasteur Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
WO2018049027A1 (en) * 2016-09-07 2018-03-15 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and pge2 antagonists
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
WO2018187698A2 (en) * 2017-04-07 2018-10-11 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
JP2019208422A (ja) * 2018-06-04 2019-12-12 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040145A (en) * 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
CA2339537A1 (en) * 1998-08-21 2000-03-02 Barbara Wallner Regulation of substrate activity
HK1046846A1 (zh) 1999-05-25 2003-01-30 Point Therapeutics, Inc. 包含boroproline的抗肿瘤复合物
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN100392074C (zh) * 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
CN101247799B (zh) * 2005-07-05 2013-03-27 塔夫茨大学信托人 成纤维细胞活化蛋白α的抑制剂
CN101379069A (zh) * 2005-12-19 2009-03-04 塔夫茨大学信托人 软蛋白酶抑制剂及其前软形式
WO2007123686A2 (en) * 2006-03-31 2007-11-01 Point Therapeutics, Inc. Dpp inhibitors and uses thereof
CA2681351A1 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
EP2154243B1 (en) * 2007-05-17 2016-01-13 ID Pharma Co., Ltd. Method for production of dendritic cell
JP5721441B2 (ja) * 2008-01-31 2015-05-20 キュアバック ゲーエムベーハーCurevac Gmbh 免疫賦活剤/アジュバントとしての式(I)(NuGlXmGnNv)aで表される核酸分子及びその誘導体
US9284337B2 (en) * 2011-11-22 2016-03-15 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines

Also Published As

Publication number Publication date
US9284337B2 (en) 2016-03-15
EP2782994A4 (en) 2015-07-15
CN106075450A (zh) 2016-11-09
US20160310513A1 (en) 2016-10-27
US20140271725A1 (en) 2014-09-18
AU2018204591A1 (en) 2018-07-12
HK1201871A1 (en) 2015-09-11
JP6240083B2 (ja) 2017-11-29
EP3106173A1 (en) 2016-12-21
JP2014533727A (ja) 2014-12-15
US9839646B2 (en) 2017-12-12
US20180092933A1 (en) 2018-04-05
AU2012340887A1 (en) 2014-07-03
EP2782994B1 (en) 2017-05-10
WO2013078059A1 (en) 2013-05-30
CN104039952A (zh) 2014-09-10
CA2856379A1 (en) 2013-05-30
EP2782994A1 (en) 2014-10-01
JP2017214420A (ja) 2017-12-07

Similar Documents

Publication Publication Date Title
ZA201306944B (en) Individualized vaccines for cancer
HUE044594T2 (hu) RNS készítmény immunterápiához
PL2581991T3 (pl) Rama nośna dla łączników wtykowych
IL228739A0 (en) Compounds to inhibit cell proliferation in egfr-driven cancers
SG10201605644WA (en) Parenteral norovirus vaccine formulations
GB201120860D0 (en) Cancer immunotherapy
GB201103600D0 (en) Dendritic cells
EP3536340B8 (en) Autologous cancer cell vaccine
SMT201900521T1 (it) Vaccini individualizzati per il cancro
ME03367B (me) Formulacija rnk za imunoterapiju
GB201201466D0 (en) Breast enhancer
GB201107549D0 (en) Cancer vaccine
IL229242A0 (en) Allogeneic cell vaccine for cancer
GB201109282D0 (en) Electrol yser